Loading clinical trials...

Advanced Understanding of Staphylococcus Aureus and Pseudomonas Aeruginosa Infections in EuRopE - ICU | Clinical Trials | Clareo Health

COMPLETED

Advanced Understanding of Staphylococcus Aureus and Pseudomonas Aeruginosa Infections in EuRopE - ICU

NCT02413242•Jan Kluytmans

View on ClinicalTrials.gov

Summary

Intensive Care Unit (ICU) acquired pneumonia, including ventilator-associated pneumonia, is a frequently occurring health-care associated infection, which causes considerable morbidity, mortality and health care costs. Important pathogens causing ICU pneumonia are Staphylococcus aureus and Pseudomonas aeruginosa. The epidemiology of ICU pneumonia and patient-related and contextual factors is not fully described, but is urgently needed to support the development of effective interventions.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Participant is 18 years or older at the time of enrollment.
•2. Participant is on mechanical ventilation at ICU admission, or is (expected to be) within 24 hours thereafter, based on investigator's judgment.
•3. Expected stay in ICU is 48 hours or longer based on investigator's judgment.
•4. SA colonization status is known within 72 hours after start of first episode of mechanical ventilation and according to the result, the patient qualifies for enrollment.
•5. Written informed consent from subject / legally accepted representative within 72 hours after start of first episode of mechanical ventilation.

Exclusion Criteria

•1. Previous participation as a subject in the study cohort of this study.
•2. Simultaneous participation of the subject in any preventive experimental study into anti-staphylococcus or anti-pseudomonas aeruginosa interventions.
•3. Expected death (moribund status) within 48h, or ICU discharge of the participant within 24h, at the moment of informed consent.

Locations (1)

UMC Utrecht

Utrecht, Netherlands

Key Dates

Start Date

April 1, 2015

Primary Completion Date

April 30, 2019

Completion Date

April 30, 2019

Last Updated

May 8, 2019

Enrollment

2,031

ACTUAL participants

Conditions

PneumoniaPneumonia, Ventilator-AssociatedNosocomial Pneumonia

Interventions

Various observed exposure(s) of interest

OTHER

Effect of Acetylcysteine Inhalation on Incidence and Time to Develop Ventilator Associated Pneumonia in Critically Ill Mechanically Ventilated Patients

NCT07409727

Ventilation Acquired Pneumonia

View study

RECRUITINGNA

Driving Pressure During Surgeries With High Risk for Postoperative Pulmonary Complications

NCT07186933

Postoperative Pulmonary AtelectasisPostoperative Pulmonary Complications+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 8, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Advanced Understanding of Staphylococcus Aureus and Pseudomonas Aeruginosa Infections in EuRopE - ICU

Inclusion Criteria

Exclusion Criteria

Effect of Acetylcysteine Inhalation on Incidence and Time to Develop Ventilator Associated Pneumonia in Critically Ill Mechanically Ventilated Patients

Driving Pressure During Surgeries With High Risk for Postoperative Pulmonary Complications

Performance of New Diagnostic Methods in Older Adults With Pneumonia

Health Systems and Policy Contexts of Medical Oxygen

High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS

Evaluating the Safety and Performance of the MiniLung Petite Kit in Neonatal and Pediatric Patients With Acute Respiratory and Cardiac Failure